Ryboquin Overview
- Founded
- 2013
- Status
- Out of Business
- Latest Deal Type
- Out of Business
Ryboquin General Information
Description
Developer of gene therapy designed to treat cancer patients. The company's gene therapy uses nano-technology, commercializes human cancer medicines and tumor apoptosis enhancer drugs to optimize chemotherapy, enabling patients to receive effective oncology therapies at an affordable cost.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Primary Office
- Ettrick Riverside, Dunsdale Road
- Scottish Borders
- Selkirk TD7 5EB
- Scotland, United Kingdom
Ryboquin Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 01-Aug-2018 | 00.000 | Completed | Out of Business | ||
| 2. Early Stage VC | 27-Jul-2017 | 00.000 | 00.000 | 00.000 | Completed | Startup |
| 1. Early Stage VC | 07-Jan-2016 | $2.19M | $2.19M | 00.000 | Completed | Startup |
Ryboquin Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary 1 | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.00 | |
| Ordinary | 000,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Ryboquin Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 | 19-Jul-2018 | 000000000000000000 | 00.000 | Other Healthcare Technology Systems | 0000 000000 |